Skip to main content

Table 1 Clinical characteristics of the patients by groups in the study

From: A radiomics model for predicting the response to methylprednisolone in brain necrosis after radiotherapy for nasopharyngeal carcinoma

Variable

Patient cohort (N = 66)

Non-effective (N = 42)

Effective (N = 24)

P value

Age, years

49 (44–56)

49 (43–56)

50 (44–56)

0.709

Sex

   

0.955

  Male

52 (78.8)

33 (78.6)

19 (79.2)

 

  Female

14 (21.2)

9 (21.4)

5 (20.8)

 

Radiomics score

− 0.940 (− 1.600–0.376)

− 1.476 (− 1.927–0.935)

0.543 (0.00–1.127)

 < 0.001

DBRN, months

41.4 (32.4–57.6)

41.6 (37.6–58.0)

40.0 (27.4–54.8)

0.212

DBRM, months

61.3 (43.3–76.2)

66.6 (45.4–76.2)

56.3 (41.3–77.8)

0.375

DBNM, months

7.3 (1.2–22.9)

9.0 (1.17–22.9)

6.1 (1.4–21.2)

0.689

AST, U/L

18.5 (16.0–22.3)

18.0 (16.0–21.3)

20 (16.3–25.0)

0.303

ALT, U/L

16.0 (13.0–23.0)

15.5 (14.0–23.3)

16.0 (10.0–22.8)

0.479

Hs-CRP, mg/L

2.4 (1.1–6.2)

2.4 (1.2–14.7)

2.4 (0.8–5.8)

0.594

Dmax of the GTVnx,Gy

70.0 (70.0–72.0)

70.0 (70.0–72.0)

70.0 (70.0–73.5)

0.264

Dmax of the GTVnd,Gy

60.0 (60.0–64.0)

60.0 (60.0–61.0)

60.0 (60.0–64.0)

0.221

Dmax of the temporal lobe, Gy

68.6 (68.6–70.6)

68.8 (68.2–70.8)

67.8 (67.2–70.0)

0.868

Radiotherapy methods

   

0.476

  Conventional radiotherapy

58 (87.9)

36 (85.7)

22 (91.7)

 

  IMRT

8 (12.1)

6 (14.3)

2 (8.3)

 

MOCA

   

0.281

  < 26

47 (71.2)

28 (66.7)

19 (79.2)

 

  ≥ 26

19 (28.8)

14 (33.3)

5 (20.8)

 

LENT-SOMA#

5 (4–6)

5 (4–6)

5 (4–6)

0.945

NPC stage

   

0.905

  II

6 (9.1)

5 (11.9)

1 (4.2)

 

  III

26 (39.4)

14 (33.3)

12 (50.0)

 

  IV

21 (31.8)

15 (35.7)

6 (25.0)

 

  IVA

13 (19.7)

8 (19.1)

5 (20.8)

 

RN volume at baseline, cm3

26.4 (8.8–59.5)

26.4 (8.3–64.2)

25.7 (8.9–45.2)

0.759

Side of FLAIR lesions

   

0.259

  Unilateral

28 (42.4)

20 (47.6)

8 (33.3)

 

  Bilateral

38 (57.6)

22 (52.4)

16 (66.7)

 

Steroid dose, mg/d

   

0.244

  80

31 (47.0)

22 (52.4)

9 (37.5)

 

  500

35 (53.0)

20 (47.6)

15 (62.5)

 
  1. Data are shown as numbers (%) or medians (interquartile ranges). P value is calculated from chi-square test for categorized variables and two-sample t-test/Mann–Whitney U test for continues variables, which represents the univariate association test of subgroups
  2. DBRN, duration between radiotherapy and radiation-induced brain necrosis (RN) diagnosis; DBRM, duration between radiotherapy and methylprednisolone treatment; DBNM, duration between RN diagnosis and methylprednisolone treatment; AST, aspartate transaminase; ALT, alanine transaminase; Hs-CRP, high-sensitivity C-reaction protein levels; Dmax of the GTVnx, the maximum radiation dose of the nasopharynx; Dmax of the GTVnd, the maximum radiation dose of the neck; IMRT, intensity-modulated radiation therapy; MoCA, Montreal Cognitive Assessment score; LENT-SOMA, the late effects of normal tissue (LENT)/subjective, objective, management, analytic (SOMA) scale score; NPC, nasopharyngeal carcinoma; RN, radiation-induced brain necrosis; FLAIR, fluid-attenuated inversion recovery
  3. # summary grade of the Subjective, Objective, and Management(SOM) characteristics
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us